Eli Lilly & Co (LLY) Stock Forecast & Price Target

Compare

18,677 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Moderate Buy

17 Buy

6 Hold

0 Sell

Based on 23 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

$910.61

▲(23.72% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $910.61 with a high forecast of $1,190.00 and a low forecast of $700.00. The average price target represents a 23.72% change from the last price of $736.03.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"699":"$699","822":"$822","945":"$945","1068":"$1,068","1191":"$1,191"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":910.61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$910.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$700.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[699,822,945,1068,1191],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,760.66,793.6861538461538,826.7123076923076,859.7384615384615,892.7646153846154,925.7907692307692,958.8169230769231,991.8430769230769,1024.8692307692309,1057.8953846153845,1090.9215384615384,1123.9476923076923,1156.9738461538461,{"y":1190,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,760.66,772.1946153846153,783.7292307692308,795.2638461538461,806.7984615384615,818.3330769230769,829.8676923076923,841.4023076923077,852.9369230769231,864.4715384615384,876.0061538461539,887.5407692307692,899.0753846153846,{"y":910.61,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,760.66,755.9938461538461,751.3276923076922,746.6615384615384,741.9953846153846,737.3292307692308,732.6630769230769,727.996923076923,723.3307692307692,718.6646153846153,713.9984615384616,709.3323076923077,704.6661538461539,{"y":700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":824.97,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 71,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":952.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":877.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":812.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":795.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":767.41,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":806.26,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":916.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":801.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":790.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":745.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":774.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":760.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,190

Average Price Target$910.61

Lowest Price Target$700.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Trung Huynh

UBS

$895

Buy

21.60%

Upside

Reiterated

08/27/25

UBS reiterates Buy Rating on Eli Lilly (LLY)UBS analyst Trung Huynh reiterated a Buy rating and $895.00 price target on Eli Lilly (NYSE: LLY).

Rajesh Kumar

HSBC

$700

Hold

-4.90%

Downside

Upgraded

08/27/25

Eli Lilly upgraded to Hold from Reduce at HSBCEli Lilly upgraded to Hold from Reduce at HSBC

Geoff Meacham

Citi

$1,190

Buy

61.68%

Upside

Reiterated

08/27/25

Citi Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

08/27/25

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Seamus Fernandez

Guggenheim

$875

Buy

18.88%

Upside

Reiterated

08/26/25

Guggenheim Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Steve Scala

TD Cowen

$960

Buy

30.43%

Upside

Reiterated

08/26/25

Eli Lilly & Co's Orforglipron Shows Promising Phase III Trial Results, Boosting Buy RatingWeight loss and A1C reductions were in line with semaglutide, but below tirzepatide. Discontinuation rates were above ideal bar. Separately, we update our LLY model. The News – Lilly announced positive topline results from the Phase III ATTAIN-2 trial of orforglipron in adults with obesity/overweight and T2D. All three doses of orforglipron tested met the primary (significant weight loss) and all secondary endpoints (A1C reduction, CV risk factor reduction).

Tim Anderson

Bank of America Securities

$1,000→$900

Buy

22.28%

Upside

Reiterated

08/26/25

Bank of America Securities Sticks to Their Buy Rating for Eli Lilly & Co (LLY)BofA Securities analyst Tim Anderson reiterated a Buy rating and $900.00 price target on Eli Lilly (NYSE: LLY).

Evan Seigerman

BMO Capital

$840

Buy

14.13%

Upside

Reiterated

08/26/25

Eli Lilly's Promising Prospects: Buy Rating Backed by ATTAIN-2 Trial Success and Strategic Growth

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

08/26/25

Eli Lilly obesity data hit higher end of expectations, says JPMorganEli Lilly obesity data hit higher end of expectations, says JPMorgan

Courtney Breen

Bernstein

$1,100

Buy

49.45%

Upside

Reiterated

08/26/25

Eli Lilly & Co (LLY) Receives a Buy from Bernstein

Veda Pharmyne

TR | OpenAI - 4o

$720→$762

Hold

3.53%

Upside

Reiterated

08/21/25

AI Generated ArticleAI Generated Article

David Risinger

Leerink Partners

―

Hold

―

Reiterated

08/18/25

Eli Lilly & Co's Orforglipron Faces Hold Rating Amid Concerns Over GI Side Effects in Clinical Trials

Narumi Nakagiri

Daiwa

$700

Hold

-4.90%

Downside

Downgraded

08/17/25

Eli Lilly downgraded to Neutral from Outperform at DaiwaEli Lilly downgraded to Neutral from Outperform at Daiwa

Asad Haider

Goldman Sachs

$876

Buy

19.02%

Upside

Reiterated

08/15/25

Positive Market Outlook for Eli Lilly's Orforglipron Following ATTAIN-1 Trial Results

Carter Gould

Cantor Fitzgerald

$975→$825

Buy

12.09%

Upside

Reiterated

08/13/25

Eli Lilly price target lowered to $825 from $975 at Cantor FitzgeraldEli Lilly price target lowered to $825 from $975 at Cantor Fitzgerald

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Trung Huynh

UBS

$895

Buy

21.60%

Upside

Reiterated

08/27/25

UBS reiterates Buy Rating on Eli Lilly (LLY)UBS analyst Trung Huynh reiterated a Buy rating and $895.00 price target on Eli Lilly (NYSE: LLY).

Rajesh Kumar

HSBC

$700

Hold

-4.90%

Downside

Upgraded

08/27/25

Eli Lilly upgraded to Hold from Reduce at HSBCEli Lilly upgraded to Hold from Reduce at HSBC

Geoff Meacham

Citi

$1,190

Buy

61.68%

Upside

Reiterated

08/27/25

Citi Keeps Their Buy Rating on Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

08/27/25

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Seamus Fernandez

Guggenheim

$875

Buy

18.88%

Upside

Reiterated

08/26/25

Guggenheim Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Steve Scala

TD Cowen

$960

Buy

30.43%

Upside

Reiterated

08/26/25

Tim Anderson

Bank of America Securities

$1,000→$900

Buy

22.28%

Upside

Reiterated

08/26/25

Bank of America Securities Sticks to Their Buy Rating for Eli Lilly & Co (LLY)BofA Securities analyst Tim Anderson reiterated a Buy rating and $900.00 price target on Eli Lilly (NYSE: LLY).

Evan Seigerman

BMO Capital

$840

Buy

14.13%

Upside

Reiterated

08/26/25

Eli Lilly's Promising Prospects: Buy Rating Backed by ATTAIN-2 Trial Success and Strategic Growth

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

08/26/25

Eli Lilly obesity data hit higher end of expectations, says JPMorganEli Lilly obesity data hit higher end of expectations, says JPMorgan

Courtney Breen

Bernstein

$1,100

Buy

49.45%

Upside

Reiterated

08/26/25

Eli Lilly & Co (LLY) Receives a Buy from Bernstein

Veda Pharmyne

TR | OpenAI - 4o

$720→$762

Hold

3.53%

Upside

Reiterated

08/21/25

AI Generated ArticleAI Generated Article

David Risinger

Leerink Partners

―

Hold

―

Reiterated

08/18/25

Eli Lilly & Co's Orforglipron Faces Hold Rating Amid Concerns Over GI Side Effects in Clinical Trials

Narumi Nakagiri

Daiwa

$700

Hold

-4.90%

Downside

Downgraded

08/17/25

Eli Lilly downgraded to Neutral from Outperform at DaiwaEli Lilly downgraded to Neutral from Outperform at Daiwa

Asad Haider

Goldman Sachs

$876

Buy

19.02%

Upside

Reiterated

08/15/25

Positive Market Outlook for Eli Lilly's Orforglipron Following ATTAIN-1 Trial Results

Carter Gould

Cantor Fitzgerald

$975→$825

Buy

12.09%

Upside

Reiterated

08/13/25

Eli Lilly price target lowered to $825 from $975 at Cantor FitzgeraldEli Lilly price target lowered to $825 from $975 at Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

1 Month

xxx

Success Rate

30/41 ratings generated profit

Average Return

+4.36%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.17% of your transactions generating a profit, with an average return of +4.36% per trade.

3 Months

xxx

Success Rate

29/41 ratings generated profit

Average Return

+8.78%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.73% of your transactions generating a profit, with an average return of +8.78% per trade.

1 Year

Chris SchottJ.P. Morgan

Success Rate

31/39 ratings generated profit

Average Return

+32.26%

reiterated a buy rating 2 days ago

Copying Chris Schott's trades and holding each position for 1 Year would result in 79.49% of your transactions generating a profit, with an average return of +32.26% per trade.

2 Years

xxx

Success Rate

25/33 ratings generated profit

Average Return

+26.54%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.76% of your transactions generating a profit, with an average return of +26.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LLY has received 76 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. LLY average Analyst price target in the past 3 months is 910.61.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is $6.36 with a range of $5.62 to $7.51. The previous quarter’s EPS was $6.31. LLY beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.43% of the time in the same period. In the last calendar year LLY has Outperformed its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is $16.04B with a range of $15.41B to $16.43B. The previous quarter’s sales results were $15.56B. LLY beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 33.83% of the time in the same period. In the last calendar year LLY has Outperformed its overall industry.

LLY Stock Forecast FAQ

What is LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 910.61.

What is LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 23.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LLY a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Moderate Buy which is based on 17 buy ratings, 6 hold ratings and 0 sell ratings.

What is Eli Lilly & Co’s price target?

The average price target for Eli Lilly & Co is 910.61. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,190.00 ,the lowest forecast is $700.00. The average price target represents 23.72% Increase from the current price of $736.03.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of LLY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts